News

Savolitinib is a highly selective and potent oral c-Met inhibitor with global first-in-class potential.  The first drug dose was administered on February 10, 2017. This Phase II study

Modus Therapeutics is currently recruiting patients in Europe, the Middle East and Caribbean in an ongoing Phase II clinical study with sevuparin for SCD. In the second half

The phase II INFORAAA clinical trial will target the second indication for Traumakine. Traumakine is based on a patent-protected use of interferon beta to prevent leakage of vascular beds

The Offer was oversubscribed and comprises 48,309,179 New Ordinary Shares to be issued by the Company (prior to any exercise of the Over-Allotment Option) Total gross proceeds raised

The Pfizer facility is a key part of the supply chain for the Company’s Glatopa products. Pfizer has indicated that the warning letter does not restrict the production

Tivantinib is an investigational oral inhibitor of the MET receptor tyrosine kinase, which is currently under phase 3 clinical development for the second-line treatment of hepatocellular carcinoma (HCC),

The study, dubbed Olympiad, was carried out in HER2-negative metastatic breast cancer patients having germline BRCA1 or BRCA2 mutations with the drug candidate trialed against physician’s choice of a

SILIQ is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have

Takeda president and CEO Christophe Weber said: “We are very pleased to have completed the acquisition of Ariad Pharmaceuticals. The addition of Ariad’s innovative targeted therapies and research